within Pharmacolibrary.Drugs.ATC.N;

model N04BX01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.65,
    Cl             = 0.00011333333333333333,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.009300000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006833333333333333,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.0112,
    k12             = 7.6,
    k21             = 7.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N04BX01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tolcapone is a reversible inhibitor of catechol-O-methyltransferase (COMT), used as an adjunct therapy in the management of Parkinson's disease. It enhances the effectiveness of levodopa by inhibiting its peripheral degradation. Tolcapone is an approved medication but its use is limited due to potential hepatotoxicity; therefore, it is restricted or withdrawn in some countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Jorga, KM, et al., &amp; Zürcher, G (1998). Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson&#x27;s disease therapy. <i>European journal of clinical pharmacology</i> 54(5) 443–447. DOI:<a href=\"https://doi.org/10.1007/s002280050490\">10.1007/s002280050490</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9754991/\">https://pubmed.ncbi.nlm.nih.gov/9754991</a></p></li><li><p>Dingemanse, J, et al., &amp; van Brummelen, P (1995). Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. <i>Clinical pharmacology and therapeutics</i> 57(5) 508–517. DOI:<a href=\"https://doi.org/10.1016/0009-9236(95)90035-7\">10.1016/0009-9236(95)90035-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7768073/\">https://pubmed.ncbi.nlm.nih.gov/7768073</a></p></li><li><p>Jorga, KM, et al., &amp; van Hattum, J (1998). Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites. <i>Clinical pharmacology and therapeutics</i> 63(6) 646–654. DOI:<a href=\"https://doi.org/10.1016/S0009-9236(98)90088-1\">10.1016/S0009-9236(98)90088-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9663179/\">https://pubmed.ncbi.nlm.nih.gov/9663179</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N04BX01;
